biostudies-literatureTherriault JWeston Brain InstituteNIA NIH HHSUK Dementia Research InstituteAlzheimer&apos;s AssociationAlzheimer's Association4967-4977https://www.ebi.ac.uk/biostudies/studies/S-EPMC10587362biostudies-literatureUnknown19(11)<h4>Introduction</h4>Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed.<h4>Methods</h4>We assessed the diagnostic performance of p-tau₁₈₁ , p-tau₂₁₇ , and p-tau₂₃₁ in plasma and CSF in 174 individuals evaluated by dementia specialists and assessed with amyloid-PET and tau-PET. Receiver operating characteristic (ROC) analyses assessed the performance of plasma and CSF biomarkers to identify amyloid-PET and tau-PET positivity.<h4>Results</h4>Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau₁₈₁ (AUC = 76%) and p-tau₂₃₁ (AUC = 82%) assessments performed inferior to CSF p-tau₁₈₁ (AUC = 87%) aAlzheimer's & dementia : the journal of the Alzheimer's AssociationEquivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.PMC10587362SG-23-1038904 QCNIRP‐12‐259245R01 AG068398UKDRI‐1003NIRG‐12‐92090NIRP-12-259245R01 AG083874SG‐23‐1038904 QCNIRG-12-92090Gauthier SStevenson JHaeger ANazneen TZetterberg HAumont EPascoal TARej SBenedet ALTherriault JKolb HCRahmouni NVitali PServaes SRosa-Neto PTriana-Baltzer GSocualaya KQTissot CAshton NJSoucy JPStevenson AFernandez-Arias JWang YTHosseini AMacedo ACKarikari TKBlennow KLussier FZfalseEquivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.<h4>Introduction</h4>Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed.<h4>Methods</h4>We assessed the diagnostic performance of p-tau₁₈₁ , p-tau₂₁₇ , and p-tau₂₃₁ in plasma and CSF in 174 individuals evaluated by dementia specialists and assessed with amyloid-PET and tau-PET. Receiver operating characteristic (ROC) analyses assessed the performance of plasma and CSF biomarkers to identify amyloid-PET and tau-PET positivity.<h4>Results</h4>Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau₁₈₁ (AUC = 76%) and p-tau₂₃₁ (AUC = 82%) assessments performed inferior to CSF p-tau₁₈₁ (AUC = 87%) a2023-01-01T00:00:00Z2023 Nov2025-04-19T18:13:45.529Z2025-04-19T18:13:45.529ZS-EPMC105873623707849510.1002/alz.13026